Healthcare provider profile · identity verified

Ashish Kumar Khemka, M.D

Internal Medicine · FORT WAYNE, IN · NPI 1992716179

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	348	62
Levothyroxine Sodium	Levothyroxine Sodium	227	38
Carvedilol	Carvedilol	192	28
Eliquis	Apixaban	177	24
Tamsulosin Hcl	Tamsulosin Hcl	156	22
Gabapentin	Gabapentin	150	24
Amlodipine Besylate	Amlodipine Besylate	129	26
Metformin Hcl	Metformin Hcl	127	21
Furosemide	Furosemide	126	30
Pantoprazole Sodium	Pantoprazole Sodium	120	25
Potassium Chloride	Potassium Chloride	120	19
Sertraline Hcl	Sertraline Hcl	107	21
Famotidine	Famotidine	106	19
Lisinopril	Lisinopril	99	19
Donepezil Hcl	Donepezil Hcl	93	15
Duloxetine Hcl	Duloxetine Hcl	89	14
Omeprazole	Omeprazole	88	21
Losartan Potassium	Losartan Potassium	80	11
Jardiance	Empagliflozin	74	suppressed
Latanoprost	Latanoprost	74	suppressed
Spironolactone	Spironolactone	60	suppressed
Finasteride	Finasteride	58	suppressed
Citalopram Hbr	Citalopram Hydrobromide	56	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	51	11
Bupropion Xl	Bupropion Hcl	50	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	49	11
Mirtazapine	Mirtazapine	49	14
Levetiracetam	Levetiracetam	48	suppressed
Tradjenta	Linagliptin	47	suppressed
Gemtesa	Vibegron	46	suppressed
Clopidogrel	Clopidogrel Bisulfate	45	suppressed
Metoprolol Succinate	Metoprolol Succinate	44	16
Pravastatin Sodium	Pravastatin Sodium	44	suppressed
Trulicity	Dulaglutide	42	suppressed
Fluticasone Propionate	Fluticasone Propionate	39	suppressed
Trazodone Hcl	Trazodone Hcl	36	suppressed
Farxiga	Dapagliflozin Propanediol	35	suppressed
Hydralazine Hcl	Hydralazine Hcl	35	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Humalog	Insulin Lispro	33	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	32	suppressed
Memantine Hcl	Memantine Hcl	32	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	suppressed
Torsemide	Torsemide	31	suppressed
Memantine Hcl Er	Memantine Hcl	30	suppressed
Prednisone	Prednisone	29	18
Diclofenac Sodium	Diclofenac Sodium	28	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	28	suppressed
Metformin Hcl Er	Metformin Hcl	28	suppressed
Entresto	Sacubitril/Valsartan	27	suppressed
Simvastatin	Simvastatin	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Baclofen	Baclofen	26	suppressed
Allopurinol	Allopurinol	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Topiramate	Topiramate	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Aptiom	Eslicarbazepine Acetate	24	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	24	23
Cyclosporine	Cyclosporine	24	suppressed
Rezvoglar Kwikpen	Insulin Glargine-Aglr	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Enulose	Lactulose	23	suppressed
Folic Acid	Folic Acid	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	18
Bumetanide	Bumetanide	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Insulin Lispro	Insulin Lispro	21	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	21	suppressed
Ondansetron Odt	Ondansetron	20	17
Ceftriaxone	Ceftriaxone Sodium	19	14
Lidocaine Hcl	Lidocaine Hcl/Pf	19	11
Benztropine Mesylate	Benztropine Mesylate	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Amoxicillin	Amoxicillin	17	suppressed
Cephalexin	Cephalexin	17	11
Doxycycline Hyclate	Doxycycline Hyclate	17	11
Meloxicam	Meloxicam	17	suppressed
Trintellix	Vortioxetine Hydrobromide	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Brilinta	Ticagrelor	16	suppressed
Methotrexate	Methotrexate Sodium	16	suppressed
Levofloxacin	Levofloxacin	15	13
Methocarbamol	Methocarbamol	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Amantadine	Amantadine Hcl	14	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	11
Diltiazem 24hr Er	Diltiazem Hcl	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Ranolazine Er	Ranolazine	14	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	14	suppressed
Colestipol Hcl	Colestipol Hcl	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Entacapone	Entacapone	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Glipizide	Glipizide	12	suppressed
Mesalamine Er	Mesalamine	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Lidocaine Hcl	Lidocaine Hcl	11	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error